U.S. markets closed

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.74+0.40 (+1.36%)
At close: 04:00PM EDT
29.72 -0.02 (-0.07%)
After hours: 06:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close29.34
Bid28.16 x 1300
Ask30.65 x 1000
Day's Range29.11 - 30.16
52 Week Range15.23 - 31.00
Avg. Volume1,366,839
Market Cap1.967B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-3.61
Earnings DateNov 13, 2023 - Nov 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CRNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Crinetics Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Zacks

    Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

    Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

  • GlobeNewswire

    Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

    SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023. Details of the fireside chat are as follows: Date: Tuesday, September 26, 2023Time: 1:00 p.m. Eastern Time The live and archived webcast will be accessible on the Events & Presentations page in the

  • Motley Fool

    Why Crinetics Pharmaceuticals Stock Soared This Week

    Shares of the rare disease specialist Crinetics Pharmaceuticals (NASDAQ: CRNX) have been on fire this week. Through the first four days of trading, the biotech's stock has already gained a healthy 81.3%, according to data provided by S&P Global Market Intelligence. The currently available therapies for acromegaly consist of injectables that can be both painful and inconvenient, given that they typically have to be administered in a doctor's office.